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Research Article
Increased nerve growth factor expression
in the synovial tissues of patients with
rotator cuff tears
Ryo Tazawa1 , Tomonori Kenmoku1 , Kentaro Uchida1,
Lars Arendt-Nielsen2, Naoshige Nagura1, Mitsufumi Nakawaki1,
Toshihide Matsumoto3, Gen Inoue1, Hiroto Takeuchi4,
Takenori Jimbo4, Toshiyuki Nakazawa4, Michinari Fukuda4, and
Masashi Takaso1
Abstract
Background: Rotator cuff tears (RCTs) are often associated with severe shoulder pain. Non-steroidal anti-inflammatory
drugs, not recommended for long-term use, do not effectively manage RCT-induced pain, resulting in reduced quality of life.
To improve management, a better understanding of the fundamental properties of RCT pain is needed. Here, we aimed to
compare the expression levels of nerve growth factor (NGF) and cyclooxygenase-2 (COX-2) mRNA in the synovial tissues
of patients with RCT-induced pain and patients with non-painful recurrent shoulder dislocation (RSD).
Methods: The study included 32 patients with RCTwho underwent arthroscopic rotator cuff repair and 28 patients with
non-painful RSD who underwent arthroscopic Bankart repair. Synovial tissue samples were harvested from subacromial
bursa and rotator interval of RCT patients and from the rotator interval of RSD patients. Samples were analyzed quanti-
tatively expression levels for NGF and COX2 mRNA and NGF protein.
Results: NGF mRNA and protein levels were significantly higher in the rotator interval of RCT patients than in the rotator
interval of RSD patients (p¼ 0.0017, p¼ 0.012, respectively), while COX2 mRNA levels did not differ significantly between
the two patient groups. In RCT patients, COX2 mRNA was more highly expressed in the rotator interval than in the
subacromial bursa (p¼ 0.038), whereas the mRNA and protein levels of NGF did not differ between the two tissues. The
expression of NGF mRNA in the synovium of the rotator interval was significantly correlated with the numeric rating scale of
pain (q¼ 0.38, p¼ 0.004).
Conclusion: NGF mRNA and protein levels were elevated in patients with painful RCT compared with those in patients
with non-painful RSD, whereas COX-2 levels were comparable in the two patient groups. These findings provide insights
into novel potential strategies for clinical management of RCT.
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Introduction
Rotator cuff tears (RCTs) increase with age1,2 and are
often associated with severe shoulder pain that leads to a
reduced quality of life. However, the size of a RCT is not
associated with pain severity,3 similar to many other
painful musculoskeletal pain conditions.4 Although the
population of patients with asymptomatic RCT is nota-
bly larger than that with symptomatic RCT,1,2 the
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mechanisms underlying why some RCT patients experi-
ence pain while others are pain-free, remain unclear.
Anti-inflammatory medications, such as non-
steroidal anti-inflammatory drugs (NSAIDs) and corti-
costeroids, are used for pain control in RCT,5 although
long-term use of traditional NSAIDs is not recom-
mended6–9 due to the risk of adverse effects.10,11
Steroid injection is another treatment modality for the
management of pain in RCT.8,9,12 However, local steroid
injections also include the risk of tendon injury progres-
sion and other adverse effects.13–16 Therefore, new ther-
apeutic targets for painful RCT are needed.
Nerve growth factor (NGF), a member of the neuro-
trophin family of proteins,17 is a modulator of pain that
is regulated during injury, inflammation, and chronic
pain conditions; and can facilitate pain.18–22 NGF local-
ization is associated with joint and tissue injuries, such as
osteoarthritic knees23,24 and degenerated intervertebral
discs,25,26 both of which are often associated with pain.
We recently reported that NGF levels are elevated in a
rat RCT model,27 and are observed in the synovial tissue
of patients with RCT28; however, a control experiment is
needed to draw definitive conclusions. Moreover, con-
sidering that NGF monoclonal antibodies are currently
being tested in various musculoskeletal conditions,29 it is
important to elucidate which conditions may represent
suitable candidates for anti-NGF treatment, from a
mechanistic standpoint.
The aim of this study was, therefore, to investigate
NGF and cyclooxygenase-2 (COX-2) expression levels
(using mRNA and protein expression) in synovial mem-
brane tissues from patients with RCT and recurrent
non-painful shoulder dislocation (RSD). To the best of
our knowledge, this is the first study to examine and
compare NGF expression levels in patients with RCT
and RSD.
Materials and methods
Ethical approval and consent to participate
This study was approved by our institutional Ethics
Review Board (reference number: KMEO B13-113).
All participants (or parents, in case of kids) provided
written informed consent prior to surgery. This study
was registered in the clinical trial registry of our country
(ID, UMIN000041077).
Patients
Samples were collected from 32 patients with painful
RCT and 28 patients with non-painful RSD between
October 2017 and November 2019. The clinical charac-
teristics of patients are summarized in Tables 1 and 2.
For evaluation of shoulder pain, the numeric rating scale
(NRS) was used (none, 0; mild, 1–3; moderate, 4–7; and
severe, >8).30 If patients experienced negligible pain,
Table 1. Clinical characteristics of patients whose samples were used for qRT-PCR analysis.
RCT RSD p value
Sample number 27 27 –
Mean age [years] 63.7 (45–84) 25.1 (15–54) < 0.001
Sex (male, female) 19, 8 20, 7 0.76
Duration after onset of RCT-induced pain or
last shoulder dislocation [months]
9.6 (2–6) 6 (0.5–40) –
NRS score 6.6 (2–10) 0.2 (0–1) < 0.001
Clinical scorea 42.3 (12–76) 47.4 (25–60) –
aRCT patients were assessed using Constant score, while RSD patients were assessed using Rowe score. qRT-PCR, quantitative reverse transcription
polymerase chain reaction; RCT, rotator cuff tear; RSD, recurrent shoulder dislocation; NRS, numeric rating scale.
Table 2. Clinical characteristics of patients who provided samples for western blotting.
RCT RSD p value
Sample number 5 5 –
Mean age in years (range) 67.8 (63–76) 34.2 (17–65) 0.036
Sex (male, female) 1, 4 3, 2 0.49
Mean duration in months after onset of RCT-induced
pain or last shoulder dislocation (range)
9.2 (2–16) 4.4 (2–8) –
NRS score 6 (3–9) 0.2 (0–1) 0.0011
Clinical scorea 45.8 (19–57) 29 (15–50) –
aRCT patients were assessed using Constant score, while RSD patients were assessed using Rowe score. RCT, rotator cuff tear; RSD, recurrent shoulder
dislocation; NRS, numeric rating scale.
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such as feeling pain only with specific motions or during
moments of heavy exertion, their pain was assessed as 1.
Additionally, the Constant score31 was used to evaluate
clinical scores for RCT patients, while RSD patients
were assessed using the Rowe score.32 The Constant
score consists of four variables used to assess shoulder
function. The subjective variables are pain and activities
of daily living (sleep, work, recreation/sport) which
account for a total of 35 points. Meanwhile, the objec-
tive variables comprise range of motion and strength
accounting for a total of 65 points. Alternatively, the
Rowe score consists of 100 points divided into three
variables, stability (0–50 points), mobility determined
by range of shoulder motion (0–20 points) and function
determined by patient activity (0–30 points).
Exclusion criteria for this study included: 1) diag-
nosed rheumatoid arthritis or other collagen diseases,
2) patients undergoing dialysis, 3) history of corticoste-
roid use including injection and/or oral formulations
within one month of operation.
Synovial tissue harvesting and preparation
RCT patients. All patients underwent arthroscopic rotator
cuff repair surgery performed by a single experienced
shoulder surgeon (K.T.). Two synovial membrane sam-
ples were harvested from each RCT patient. One sample
was obtained from the site of the most marked synovitis
in the rotator interval (Figure 1(a) and (b)) and the other
was obtained from a site in the subacromial bursa
(Figure 1(a) and (c)) around a coracoacromial ligament
where the greater tuberosity of the humeral head was
usually impinged.
RSD patients. All patients underwent arthroscopic
Bankart repair by a single experienced shoulder surgeon
(K.T.). Samples of the synovial membrane of the rotator
interval were harvested from each RSD patient. Samples
were not harvested from the subacromial space around a
coracoacromial ligament in these patients as there is a
possibility of iatrogenic pain in patients with RSD, and
the institutional Ethics Review Board did not permit
sampling from healthy or unaffected areas in these
patients.
All samples were immediately frozen in liquid nitro-
gen and stored at 80C until RNA extraction for quan-
titative reverse transcription polymerase chain reaction
(qRT-PCR) and protein extraction for western blotting.
qRT-PCR analysis
To investigate differences in mRNA expression of NGF
and COX2 between RCT and RSD patients, qRT-PCR
analysis was performed on synovial membrane tissue
obtained from each group (n¼ 27 per group). TRIzol
(Invitrogen, Carlsbad, CA, USA) was used to extract
total RNA from the synovial membrane, according to
the manufacturer’s protocol. Total RNA was used as a
template for first-strand cDNA synthesis using a
SuperScript III RT (Invitrogen). A 25-mL reaction com-
prising 2 mL cDNA, a specific primer set (0.2 mM final
concentration; Table 3), and 12.5 mL SYBR Premix Ex
Taq (Takara, Shiga, Japan) were used for qRT-PCR.
Primers for NGF and COX2 were designed using the
Primer-Blast tool from NCBI, and synthesized by
Hokkaido System Science Co., Ltd. (Sapporo, Japan).
qRT-PCR was conducted on a CFX-96 Real-Time PCR
Figure 1. Scheme of the shoulder joint anatomy (a), where tissue was obtained from each group of patients. Representative arthroscopic
view of intra articular (b) and subacromial space (c). *Synovial tissue of rotator interval; **Synovial tissue of subacromial bursa; †rotator
cuff tear; HH, humeral head; Ac, acromion; SSc, subscapularis; SSp, supraspinatus; LHB, long head of biceps tendon.










F, forward; R, reverse; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
NGF, nerve growth factor; COX2, cyclooxygenase-2.
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Detection System (Bio-Rad, Hercules, CA, USA) using
the following protocol: initial denaturation at 95C for
1min, 40 cycles at 95C for 5 s, and 60C for 30 s. The
specificity of the primer-amplified products was con-
firmed using melting curve analysis, and NGF and
COX2 mRNA expression was determined by normaliz-
ing to that of glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) using the delta-delta Ct method.33 We
then evaluated the correlation between gene expression
and NRS.
Western blotting
To investigate differences in NGF abundance between
RCT and RSD patients, western blotting was performed
on synovial membrane obtained from both study groups
(n¼ 5 per group). Synovial membranes were lysed in
radioimmune precipitation buffer (Wako Pure
Chemical Co., Inc., Osaka, Japan) containing a protease
inhibitor cocktail (Roche, Madison WI, USA), and the
protein concentration in each lysate was quantified using
the bicinchoninic acid (BCA) assay (Pierce, Rockford,
Illinois, USA). Proteins (10 mg/lane) were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and were electro-transferred onto poly-
vinylidene fluoride (PVDF) membranes (Pierce), which
were then blocked with PVDF blocking reagent (DS
Pharma Biomedical, Suita, Japan) for 1 h at room tem-
perature (22–25 C). The blocked membranes were incu-
bated overnight at 4C with rabbit polyclonal primary
antibodies against NGF (cat. no: ab52918; Abcam)
diluted 1:1000 in blocking reagent (ImmunoBlock, DS
Pharma). The membranes were washed with phosphate-
buffered saline (PBS, pH 7.4) containing 0.05% Tween
and incubated with secondary antibodies (GE
Healthcare, Piscataway NJ, USA) diluted 1:1000 in
blocking reagent. Immunoreactive proteins were visual-
ized based on chemiluminescence using an ECL detec-
tion system (GE Healthcare) and exposing the
membranes to x-ray film. Each band was quantified by
densitometric scanning using the NIH software ImageJ
version 1.8.0_112. The densitometric readings of the
bands were normalized to those of b-actin.
Immunohistochemistry
Synovial tissue samples were embedded in paraffin and
sliced into 3-mm-thick sections, which were deparaffi-
nized in xylene for 1 h, hydrated in serial dilutions of
ethanol, and rinsed in distilled water. For antigen
retrieval, deparaffinized sections were heated in Tris/
EDTA (pH 9) at 98C for 40 min. Endogenous perox-
idases were blocked by incubating the sections in 3%
hydrogen peroxide prepared in methanol for 15 min.
The samples were washed with PBS and incubated
with 10% goat serum (Nichirei, Tokyo, Japan) for 10
min at room temperature (22–25C). Next, the sections
were incubated with anti-NGF monoclonal rabbit IgG
(cat.no: ab6199, Abcam) for 3 h and proteins were visu-
alized using the streptavidin-biotin-peroxidase method
(Histofine SAB-PO Kit; Nichirei). Sections were coun-
terstained with Meyer’s hematoxylin. Negative controls
were also included in which incubation with the primary
antibody was omitted.
Statistical analysis
Data are presented as mean standard error. The results
of qRT-PCR and western blotting did not have equal
variance. Hence, differences between 1) the subacromial
bursa and rotator interval samples from RCT patients,
and 2) rotator interval samples from RCT and RSD
patients were determined using the Mann-Whitney-U
test. Correlations between the mRNA levels of NGF,
COX2 and NRS, and age were determined using
Spearman’s rank correlation coefficient. All statistical
analyses and power analyses were performed using the
SPSS software (version 19.0; SPSS, Inc., Chicago, IL,
USA), and p< 0.05 was considered statistically signifi-
cant. The classification scheme for the correlation was
defined as follows: 0< |q|  0.2, negligible; 0.2< |q| 
0.4, low; 0.4< |q|  0.7, moderate; 0.7  |q|, high.
Results
Expression levels of NGF and COX2 mRNA in RCT
and RSD patients
The samples obtained from sites with the highest degree
of synovitis in the rotator intervals showed a significant
difference in NGF mRNA expression between the RCT
and RSD groups (p¼ 0.0017, q¼ 0.92; Figure 2(a),
Table 4). However, no significant difference was
observed in COX2 mRNA expression between these
two groups (p¼ 0.59, q¼ 0.07; Figure 2(b), Table 4).
In the RCT group, no significant difference was
observed in the expression levels of NGF mRNA
between the subacromial bursa and synovial membrane
in the rotator interval (p¼ 0.28, power¼ 0.06; Figure 2
(a), Table 4). Meanwhile, the expression of COX2
mRNA in the subacromial bursa was significantly
lower than that in the rotator interval synovial mem-
brane (p¼ 0.039, q¼ 0.24; Figure 2(b), Table 4).
Correlation between mRNA expression of NGF and
COX2 and age
Samples obtained from sites with the most marked syno-
vitis in the rotator intervals showed no significant cor-
relation between NGF and COX2mRNA expression and
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age (p¼ 0.12, 0.59, respectively; q¼ 0.17, 0.061, respec-
tively; Figure 3).
Correlation between the mRNA levels of NGF,
COX2 and NRS
NGF mRNA expression in the rotator interval correlat-
ed with NRS (q¼ 0.38, p¼ 0.004; Figure 4(a)). However,
no correlation was observed between COX2 mRNA
expression in the rotator interval and NRS (q¼ -0.006,
p¼ 0.97; Figure 4(b)). Additionally, no correlation was
observed between NGF and COX2 mRNA expression in
the subacromial bursa of RCTs and NRS (q¼ 0.08,
p¼ 0.69; q¼0.24, p¼ 0.22, respectively; Figure 5).
NGF protein expression and localization in
synovial tissue
The abundance of NGF protein in the synovial mem-
brane is shown in Figure 6. Rotator interval samples
from the RCT patients showed significantly higher
NGF protein abundance than those from RSD patients
(RCT vs RSD, 1.08 0.34 vs 0.12 0.05, p¼ 0.012,
power¼ 0.68; Figure 6(b)). However, no significant dif-
ferences were observed between the subacromial bursa
and synovial membrane in the rotator interval of RCT
patients (subacromial bursa of RCT vs rotator interval
of RCT, 1.08 0.34 vs 0.46 0.20, p¼ 0.095, power¼
0.28; Figure 6(b)). Furthermore, immunohistochemistry
revealed the presence of NGF-positive cells in the lining
layer of the synovial tissue of RCT patients (Figure 7(a)
and (b)), while few NGF-positive cells were observed in
the synovial tissue of RSD patients (Figure 7(c)). NGF
staining was not seen in negative control sections
(Figure 7(d) to (f)).
Discussion
Results show that NGF expression was significantly
higher in the synovial tissue of patients with RCT than
in patients with RSD, while no significant difference was
observed in COX2 expression between the two groups.
NGF protein expression was higher in the synovium of
the rotator interval in patients with RCT than in patients
with RSD. Further, the mRNA expression of NGF in the
rotator interval synovium significantly correlated with
NRS. Moreover, NGF-positive cells localized in the
lining layer of the synovial tissue in patients with
RCT, but this was not observed in the synovial tissue
of RSD patients.
NGF mRNA has been detected in a human mast cell
line34 and NGF is also reportedly present in, and
released from, human CD14þ T cell clones and human
monocytes that differentiate rapidly during tissue
damage.35,36 The data of the relationship between
NGF and peripheral sensitization supports the pronoci-
ceptive functions of NGF that may include driving local
neuronal sprouting at the site of tissue injury.37 In
Figure 2. Quantitative polymerase chain reaction for analyzing the mRNA expression of NGF (a) and COX2 (b) in the synovial tissue of
the RI of patients with RSD, the SAB of patients with RCT, and synovial tissue of the RI of patients with RCT and. Gene expression was
normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). *p¼ 0.0017, between the RI of RCT and RSD
patients. †p¼ 0.039, between the SAB of RCT patients and the RI of RCT patients. NGF, neural growth factor; COX2, cyclooxygenase-2;
SAB, subacromial bursa; RI, rotator interval; RSD, recurrent shoulder dislocation; RCT, rotator cuff tear.
Table 4. NGF and COX2 expression levels in RCT and RSD
patients.
RI of RCT RI of RSD p value (q)
NGF 0.0035 0.0004 0.0021 0.0002 0.0017 (0.92)
COX2 0.0021 0.0003 0.0022 0.0003 0.59 (0.07)
RI of RCT SAB of RCT
NGF 0.0035 0.0004 0.0037 0.0006 0.28 (0.06)
COX2 0.0021 0.0003 0.0015 0.0003 0.039 (0.24)
Boldface to enhance the values that shows significant difference between
two groups.
COX2, cyclooxygenase-2, NGF, nerve growth factor; RCT, rotator cuff
tear; RSD, recurrent shoulder dislocation; RI, rotator interval; SAB, sub-
acromial bursa.
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Figure 3. Correlation between the mRNA levels of NGF (a), COX2 (b) and age in the synovial tissue of rotator intervals. NGF, nerve
growth factor; COX2, cyclooxygenase-2; white circle, synovium in rotator interval of recurrent shoulder dislocation; black circle,
synovium in rotator interval of rotator cuff tears; black triangle, synovium in subacromial bursa of rotator cuff tears; dotted line,
regression line.
Figure 4. Correlation between the mRNA levels of NGF (a), COX2 (b) and numeric rating scale of pain in the synovial tissue of rotator
intervals. NGF, nerve growth factor; COX2, cyclooxygenase-2; white circle, synovium in rotator interval of recurrent shoulder dislocation;
black circle, synovium in rotator interval of rotator cuff tears; dotted line, regression line.
Figure 5. Correlation between the mRNA levels of NGF (a) and COX2 (b) and the numeric rating scale of pain in the synovial tissue of the
subacromial bursa. NGF, nerve growth factor; COX2, cyclooxygenase-2; black circle, synovium in the subacromial bursa of rotator cuff
tears; dotted line, regression line.
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addition, the administration of anti-NGF antibody has
been found to inhibit ectopic sprouting of sensory and
sympathetic nerve fibers in an experimental mouse
model of arthritis.38 Sensory nerves, free nerve endings,
and expression levels of nociceptive receptors are all
increased in the subacromial bursa and around the rota-
tor interval with RCTs.39 Meanwhile, NGF has recently
become the focus of research for the treatment of mus-
culoskeletal chronic pain,4,23–26 with NGF monoclonal
antibodies currently being tested in clinical settings.40
NGF is associated with sensitizing nociceptors through
the transient receptor potential cation channel subfamily
V member 1 receptor41; which is believed to be one of the
links to pain and, hence, peripheral sensitization induced
by NGF may be one of the causes of pain associated
with RCT. In the present study, NGF mRNA and pro-
tein expression levels were found to be higher in the
synovial membrane of patients with RCT than in that
of patients with RSD. Considering that NGF expression
in the rotator interval samples showed a significant pos-
itive correlation with the NRS of pain and immunohis-
tochemistry revealed the presence of NGF-positive cells
in the lining layer of the synovial tissue of RCT patients,
rotator cuff injury may trigger increased NGF expres-
sion in the synovial tissue. Our findings, together with
existing literature, suggest that elevated NGF expression
may be a promising target (TRKA-inhibition or NGF
monoclonal antibodies) for pain management in patients
with RCT.
NGF levels in synovial fluid are increased in patients
with osteoarthritis (OA), rheumatoid arthritis, and spon-
dyloarthritis.42–44 Additionally, NGF levels are
increased in synovial specimens from patients with
advanced OA compared with those in non-OA controls,
as well as in specimens from patients exhibiting symp-
tomatic chondropathy compared with those from
patients with asymptomatic chondropathy.45 Here, we
confirmed that NGF mRNA and NGF protein expres-
sion levels in the synovial membrane were significantly
higher in patients with RCT than in patients with RSD.
In addition, no significant difference was observed in
mRNA and protein levels of NGF between the subacro-
mial bursa and rotator interval synovium. These results
are consistent with those from animal experiments that
showed that NGF levels are elevated for up to 56 d after
RCT.27 Taken together, these studies suggest that NGF
Figure 6. NGF expression measured in synovial membrane from
the SAB and RI of patients with RCT and RI of patients with RSD
patients by (a) western blotting and (b) normalized to the
expression of b-actin. (n¼ 5 per group). *p¼ 0.012, between the
RI of RCT and RSD patients. NGF, nerve growth factor; SAB,
subacromial bursa; RI, rotator interval, RCT, rotator cuff tear;
RSD, recurrent shoulder dislocation; white circle, synovium in
rotator interval of recurrent shoulder dislocation; black circle,
synovium in rotator interval of rotator cuff tears.
Figure 7. Immunolocalization of NGF (black arrows) in the synovial tissue of the SAB (a) and RI (b) of RCT patients, and RI of RSD
patients (c. (d to f) Negative control sections in each patient are shown. NGF, nerve growth factor; SAB, subacromial bursa; RI, rotator
interval; RCT, rotator cuff tear; RSD, recurrent shoulder dislocation; Scale bar¼ 100 lm.
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could be associated with some of the underlying mecha-
nisms of rotator cuff-related pain.
NGF levels are frequently elevated in inflamed states
and have been linked to OA pain and lower back pain
that could both be reduced with an NGF-neutralizing
monoclonal antibody.46–48 Moreover, the anti-NGF
antibody improved pain behavior in a COX-2 inhibi-
tor-resistant rat OA model.49 In the present study,
COX2 expression in the rotator interval samples from
the RCT group showed no significant difference com-
pared to that in the rotator interval samples from the
RSD group. Previous reports have shown that COX-2
levels in the subacromial bursa of patients with RCT are
increased compared with those in the subacromial bursa
of patients with RSD based on an immunohistochemical
grading scale; however, these levels have not been quan-
titatively assessed.50 We previously reported that COX2
upregulation was reduced 14 d after RCT in a rat
model.27 Moreover, a COX-2 inhibitor can induce
NGF expression in the human synovium.28 Our findings
suggest that degenerative RCT-associated pain depends
on factors other than COX-2, and, therefore, some
patients with RCT may not benefit from short-term
NSAID treatment.
In this investigation, the mean age of patients with
RCT was significantly higher than that of patients with
RSD; therefore, age may affect NGF and COX-2
expression. However, in our study, no correlation
existed between the mRNA expression of NGF and
COX2 and age (Figure 3). Further, RCT are potentially
degenerative disorders,1–3 while the rotator cuff is com-
monly damaged during shoulder dislocation in elderly
patients.51 Therefore, it is difficult to obtain a large
enough number of RSD patients without RCT in
middle or elderly age. In addition, COX-2 expression
and immunoreactivity are significantly decreased with
aging in mouse hippocampus.52 The mean expression
level of COX2 may be associated with the difference in
age between the RCT and RSD groups. In addition, our
findings indicate that COX-2 may not be a main con-
tributor to pain in RCT.
Limitations
This study had some limitations. First, the power of the
western blotting results is relatively low, due to the small
sample size. PCR and western blotting could not be per-
formed on the same samples due to the limited sample
volume collected from each patient. Therefore, the scat-
ter plot of mRNA and protein levels for each patient
could not be created. A healthy control group was not
included in this study. Second, we could not—for ethical
reasons—harvest synovial membrane samples from the
subacromial bursa of RSD patients, and every patient
with RSD in this study did not show subacromial
impingement symptoms. A previous report showed
that COX2 mRNA levels in the subacromial bursa of
RSD patients were significantly lower than those in the
subacromial bursa of RCT patients,50 while in this
study, there was no significant difference in either NGF
or COX2 expression between the subacromial bursa and
rotator interval synovial membrane in RCT patients.
Therefore, our findings have not been influenced by
the expression of these genes in the subacromial bursa
of patients with RSD.
In conclusion, the synovial membrane of patients
with RCT exhibits a significantly higher expression of
NGF mRNA and protein than that of patients with
RSD, but no significant difference in COX2 expression.
Conclusion
This study supports further investigations of NGF as a
potential therapeutic target for pain in patients with
RCT, whereas the interaction with the COX-2 pathways
may not be a promising target.
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